Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Atomo Revenue Jumps as HIV and Syphilis Tests Advance

AT1: $0.015 -6.25% · MC: $11M

Atomo Diagnostics reported first-quarter revenue of approximately $2 million, up 140% year on year, with HIV sales rising 38% and FebriDx and other OEM revenue increasing sharply from a lower base. The company also signed an agreement to develop a fourth-generation HIV test with Innovation Scientific, while its Active Syphilis test has transferred to manufacturing ahead of planned clinical trials. Atomo ended the quarter debt-free with approximately $3 million in cash; the HIV test launch and regulatory approvals remain planned, not secured.

Source announcements: 2026-10-29 09:43 to 2026-10-29 17:10 Sydney time
Story updated 2026-10-29 17:13 Sydney time
SourcesAtomo Signs Agreement with Innovation ScientificQuarterly Activities/Appendix 4C Cash Flow ReportQ1 FY27 Results Presentation
Comments